Samsung Bioepis plans to soon initiate global late-stage studies of SB8, its investigational biosimilar of Roche's Avastin, The Korea Herald reported.
According to the EU Clinical Trials Register, the 678-patient trial will take place across 10 countries in Europe, as well as Taiwan and Korea.
The drugmaker declined to confirm the exact starting date of the trial.
The company has already received clearance from Korea's Ministry of Food and Drug Safety to initiate Phase III trials.
To read more NewsPoints articles, click here.